# Lazertinib/Pemetrexed/Carboplatin After Osimertinib Failure in NSCLC With Brain Metastases

> **NCT05477615** · PHASE2 · UNKNOWN · sponsor: **Jin Hyoung Kang** · enrollment: 28 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Lazertinib
- **DRUG:** Pemetrexed
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT05477615
- **Lead sponsor:** Jin Hyoung Kang
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-08
- **Primary completion:** 2023-06
- **Final completion:** 2025-06
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2022-07-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05477615

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05477615, "Lazertinib/Pemetrexed/Carboplatin After Osimertinib Failure in NSCLC With Brain Metastases". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05477615. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*